Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2020, specifically detailing a corporate action announced on January 9, 2020. The Company, a biopharmaceutical firm based in Israel, entered into warrant exercise agreements with accredited investors to raise capital for its clinical development programs.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.4 million from the exercise of public warrants.
- Shares Issued: Up to 22,278,540 Ordinary Shares (represented by 742,618 ADSs).
- Exercise Price: Reduced to $3.25 per ADS (original prices ranged from $12.90 to $78.75).
- Placement Agent Fees: 7.0% of the aggregate number of ADSs placed plus a $35,000 expense allowance, plus warrants for 7.0% of the ADSs placed.
- Private Placement Warrants: New warrants issued to holders for 22,278,540 Ordinary Shares at an exercise price of $3.45 per ADS, exercisable immediately and expiring in 5.5 years.
- Net Proceeds: The filing does not provide a clear value for net proceeds after deducting fees and expenses.
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide a clear value for these standard financial metrics as this is a transaction-specific report, not a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the dilution of existing shareholders through the issuance of new shares and warrants at a significantly reduced exercise price. The Company intends to use the net proceeds for working capital, specifically to fund:
- Progression of Phase III studies for psoriasis and rheumatoid arthritis.
- Preparatory work for a Phase III liver cancer study.
- Other general corporate purposes.
Outlook, Risks, and Contingencies
Management Commentary: The transaction was negotiated individually with holders to secure immediate capital for critical clinical trials. The Company engaged H.C. Wainwright & Co., LLC as the exclusive placement agent.
Risks and Contingencies:
- Registration Status: The Private Placement Warrants and underlying ADSs are unregistered and may not be sold in the U.S. except pursuant to an effective registration statement or exemption.
- Cashless Exercise: Private Placement Warrants may be exercised on a cashless basis if no effective registration statement is filed six months after issuance.
- Dilution: The issuance of new shares and warrants at prices below the original exercise prices represents a dilutive event.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7% placement fee and $35,000 expense allowance.
- Confirm the current cash balance and runway to ensure the $2.4 million gross proceeds are sufficient to complete the stated Phase III studies.
- Review the full terms of the Private Placement Warrants (Exhibit 10.2) regarding anti-dilution adjustments and cashless exercise provisions.
- Monitor the status of the registration statements for the underlying ADSs to determine if the cashless exercise contingency is triggered.